Cell migration and angiogenesis are key steps in tumor metastasis. However, the mechanism of migration regulated by vascular endothelial growth factor (VEGF), a potent regulator of angiogenesis, is not completely understood. This study examined the relationship between VEGF and migration, along with the mechanism involved in the VEGF-regulated migration of human gastric cancer cells. The level of cell migration was increased by recombinant human (rh)VEGF-165 in the VEGF receptor-2-expressing SNU-601 cells. Interleukin (IL)-18 is associated with the malignant progression of tumors. Accordingly, this study examined the effect of IL-18 on the migration of cancer cells in order to identify the factors involved in VEGF-enhanced migration. Inhibiting IL-18 markedly reduced the level of VEGF-enhanced migration, and IL-18 increased cell migration directly through filamentous-actin polymerization and tensin downregulation. It was confirmed that rhVEGF-165 increased IL-18 production significantly. An antioxidant and an extracellular signal-regulated kinase (ERK)1/2-specific inhibitor blocked rhVEGF-165-enhanced IL-18 production. Accordingly, rhVEGF-165 increased the generation of region of interest (ROI) and activated the ERK1/2 pathway. These results suggest that rhVEGF-165 enhances IL-18 production via the generation of ROI and ERK1/2 phosphorylation, which results in the increased migration of gastric cancer cells.
Introduction
Malignant tumors, such as melanoma, breast cancer and gastric cancer, metastasize. This process promotes tumor progression by allowing malignant tumor cells to invade the blood or lymphatic vessels, and migrate to other tissues or organs. A metastasis is generally associated with a poor prognosis in tumor patients. Angiogenesis is a key step in metastatic process. Solid tumors cannot grow to more than 1-3 mm 3 without requiring an independent supply of essential nutrients and oxygen. During tumor growth, the tumor cells are under hypoxic conditions, which activate the hypoxia-inducible factor that increases the expression of various angiogenic factors. These factors are involved in increasing the angiogenic activity and disease progression in many carcinomas. Tumor cells can metastasize after new blood vessels form around a tumor. This study investigated the angiogenic factors in tumor cells focusing mainly on vascular endothelial growth factor (VEGF), which is a major factor mediating the survival, migration and proliferation of endothelial cells during angiogenesis (Carmeliet and Jain, 2000) . An increase in VEGF expression is associated with increased tumor growth and the metastatic spread of solid malignancies (Takahashi et al., 1995) . In humans, VEGF exists in six isoforms through alternative splicing, such as VEGF-121, . Among these VEGF isoforms, VEGF-121 and VEGF-165 are the main isoforms. It has been reported that VEGF exerts its cellular functions by interacting with VEGF receptors, which are found in many gastric cancer cell lines (Zhang et al., 2002) . ) is a proinflammatory cytokine and is considered to be a member of the IL-1 cytokine family on account of it possessing a structure similar to IL-1. IL-18 is converted from a 24 kDa inactive form, which does not contain any signal peptides, to an 18 kDa bioactive form as a result of cleavage by an IL-1b-converting enzyme. The 18 kDa active form of IL-18 is then secreted. This active IL-18 stimulates interferon (IFN)-g production directly, which is known as the IFN-g-inducing factor. IL-18 is produced by macrophages, keratinocytes, dendritic cells as well as by tumor cells (Okamura et al., 1995; Stoll et al., 1997; Udagawa et al., 1997) . It has been reported that IL-18 is involved in the immune escape of tumor cells, such as melanoma cells (Cho et al., 2000) . In addition, IL-18 increases tumor cell proliferation in gastric cancer, and plays a prometastatic role in human and murine melanoma cell lines (Carrascal et al., 2003; Majima et al., 2006) . The ability of cells to migrate is essential during the metastatic process. Cell migration plays an important role in the inflammatory immune response and tumor formation (Horwitz and Parsons, 1999) . It was demonstrated that VEGF regulates the migration of metastatic prostate cancer cells through VEGF receptor-2 (Chen et al., 2004) , and IL-18 induces the migration of Langerhans cells and natural killer (NK) cells (Cumberbatch et al., 2001; Ishida et al., 2004) . Although both angiogenic factors, particularly VEGF and IL-18, are related to the metastatic potential of some tumor cells, the relationship between VEGF and IL-18 and with the effect of IL-18 on enhancing tumor cell migration in gastric cancer are not completely understood. The results show that VEGF increases the migration of human gastric cancer cells through VEGF-enhanced IL-18 production.
Results

IL-18 is a critical mediator of VEGF-enhanced migration
The expression of VEGFR-2 and the effect of rhVEGF-165 on the migration were examined to determine if rhVEGF-165 increases the level of SNU-601 cell migration. Figure 1a shows that VEGFR-2 was strongly expressed on the SNU-601 cells. A dose titration of a specific VEGFR-2 inhibitor, SU5416, was performed in order to determine if rhVEGF-165 has specific functions via VEGFR-2. As shown in Figure 1b and c, when 50 ng/ml of rhVEGF-165 was treated for 48 h, the migration of SNU-601 cells was decreased, and the spontaneous cell migration was decreased significantly by SU5416 in a dose-dependent manner within 24 h. In addition, SNU-601 cells produced VEGF-165 spontaneously (Figure 1d ). It was hypothesized that IL-18 is an important mediator in VEGF-enhanced migration because it was reported that VEGF and IL-18 are related to the metastatic potential of many malignant cancers (Takahashi et al., 1995; Carrascal et al., 2003) . As a first step to study the involvement of IL-18 in VEGF-enhanced migration, we investigated the effect of a specific inhibitor of IL-18, IL-18-binding protein (IL-18BP). Figure 2a and b show that VEGF-enhanced migration was reduced significantly by IL-18BP. In addition, the migration rate of IL-18 small interfering RNA (siRNA) transfectant was considerably lower than the control cells (Figure 2c ). Moreover, rhVEGF-165 did not enhance the migration ability of the IL-18 siRNA transfectant (Figure 2d ), suggesting that IL-18 plays a key role in the VEGF-enhanced migration of SNU-601 cells.
IL-18 increases directly the migration of gastric cancer cells through F-actin polymerization and tensin down-regulation To examine the direct effect of IL-18 on the migration of SNU-601 cells.rhIL-18 was used As shown in Figure 3a and b, the addition of 150 ng/ml of rhIL-18 to IL-18 receptor-expressing SNU-601 cells increased the rate of cell migration significantly. The difference in the level of SNU-601 cell migration between the control and rhIL-18-treated cells was most obvious when SNU-601 cells were incubated in the Transwell chambers for 24 h. rhIL-18 increased the migration of SNU-601 cells in a manner both dose-and time-dependent (Figure 3c and d). In addition, rhIL-18 increased the invasive ability of SNU-601 cells approximately twofold (Figure 3e ). The mechanism of IL-18-increased migration in SNU-601 cells was investigated. It is known that f-actin is polymerized in migrating cells, and the expression level of tensin, which is a capping protein of f-actin, is markedly lower in malignant tumor cells (Lo et al., 1994; Meili and Firtel, 2003; Lo, 2004) . Based on these reports, this study examined whether or not f-actin polymerization and tensin expression were associated with IL-18-increased migration. The cells pretreated with 1 mg/ml of cytochalasin D, an f-actin-depolymerizing agent, for 1 h showed a significant decrease in IL-18-increased migration (Figure 4a ). F-actin polymerization was detected mainly in cortical region by IL-18, resulting in change in the cell morphology to an annular structure ( Figure 4b ). According to f-actin polymerization, it was hypothesized that IL-18 may decrease the expression of tensin in migrating cells. As shown in Figure 4c , tensin expression was much higher in the IL-18 siRNA transfectant than in the control cells. This effect was inhibited by rhIL-18. This suggests that IL-18 increases the migration of SNU-601 cells through tensin downregulation, which enhances f-actin polymerization.
rhVEGF-165 enhances IL-18 production in gastric cancer cells The effect of rhVEGF-165 on IL-18 production in SNU-601 cells was examined by reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) to confirm that rhVEGF-165 enhances IL-18 production, which results in increased migration. IL-18 mRNA expression was increased significantly by a treatment with 50 ng/ml rhVEGF-165 for 1 h (Figure 5a ). IL-18 production was also enhanced by rhVEGF-165 in both a time-and a dose-dependent manner (Figure 5b and c) . A dose titration of SU5416 was performed to determine if VEGF enhances IL-18 production via VEGFR-2. In the absence of rhVEGF-165, SU5416 reduced the spontaneous production of IL-18 in a dose-dependent manner (Figure 5d ). The effect of rhVEGF-165 on IL-18 production in other gastric cancer cell lines, such as MKN-28 and SNU-719 cells, was examined to determine if the effect of rhVEGF-165 on IL-18 production is common to a variety of gastric cancer cells. Table 1 shows that MKN-28 and SNU-719 cells also express VEGFR-2. Compared with the control for each cell line, rhVEGF-165 increased IL-18 production. In addition, the migration rate of these gastric cancer cell lines was increased by rhVEGF-165 and rhIL-18 (Table 2 ). This indicates that rhVEGF-165 can enhance the migratory properties in many gastric cancer cells by upregulating IL-18 production.
Generation of ROI and activation of ERK1/2 MAPK pathway are required for VEGF-enhanced IL-18 production Region of interest (ROI) plays an important role in the intracellular signal-transduction pathways, including the regulation of inflammatory cytokine production, such as tumor necrosis factor-a (Gossart et al., 1996) . An antioxidant, N-acetyl-L-cysteine (NAC), was used to determine if ROI are involved in VEGF-enhanced IL-18 production. NAC significantly decreased VEGFenhanced IL-18 production. rhVEGF-165 stimulation increased the level of ROI, indicating that rhVEGF-165 enhances IL-18 production through the generation of ROI (Figure 6a and b) . The signaling pathway for VEGF-enhanced IL-18 production was further examined by investigating whether or not extracellular signalregulated kinase (ERK)1/2 and c-Jun NH 2 -terminal kinase (JNK) mitogen-activated protein kinase pathways are involved in VEGF-enhanced IL-18 production using a specific inhibitor of ERK1/2 (PD98059) and JNK (SP600125). PD98059 increased VEGF-enhanced IL-18 production in a dose-dependent manner, but SP600125 had no effect (Figure 6c and d) . Accordingly, SNU-601 cells were incubated with 50 ng/ml of rhVEGF-165 for 2.5, 5, 10 and 15 min. ERK1/2 phosphorylation was determined using Western blot analysis. Figure 6e shows that rhVEGF-165 increased ERK1/2 phosphorylation, and reached a maximum at 5 min, which indicates that rhVEGF-165 stimulates ERK1/2 phosphorylation directly. This shows that rhVEGF-165 enhances IL-18 production via the activation of ERK1/2. Discussion IL-18 was identified as being an IFN-g-inducing factor. Moreover, the active IL-18 protein increases IFN-g production from immune cells, such as T or NK cells, to develop Th1 cells and augment the activity of NK cells (Okamura et al., 1995) . Some reports have suggested that IL-18 inhibits angiogenesis, suppresses tumor growth and enhances the anti-tumor responses (Cao et al., 1999; Ju et al., 2001) . Although IL-18 can enhance the immune response, it was recently reported that tumors could counterattack the immune system by secreting IL-18 (Cho et al., 2000) . The serum IL-18 concentration was reported to be higher in metastatic cancer patients than in early cancer patients, and the metastatic ability of melanoma is regulated by IL-18 via vascular cell adhesion molecule-1 (Lissoni et al., 2000; Vidal-Vanaclocha et al., 2000) . This suggests that the IL-18 derived from cancer cells is involved in the cancer metastatic process. In contrast to a study demonstrating that IL-18 plays a role as an angiogenesis inhibitor, it was recently reported that IL-18 induces angiogenesis in rheumatoid arthritis, which suggests a novel proangiogenic function of IL-18 (Park et al., 2001) . Angiogenesis is essential for tumor progression and metastasis, and proangiogenic factors are beneficial to tumor cells. In particular, VEGF is the most potent mediator of (b) SNU-601 cells were incubated with or without 150 ng/ml of rhIL-18 on slides. After incubation, immunostaining was performed. Image was collected using a confocal microscopy system; bars, upper panels: 20 mm, lower panels: 5 mm. (c) IL-18 siRNAtransfected cells were treated with or without 150 ng/ml of rhIL-18 for 24 h. After cell lysis, immunoprecipitation was performed. The expression of tensin was determined by Western blot analysis. Actin was used to confirm the equal volume of the cell lysates.
angiogenesis. The results in this study showed that rhVEGF-165 enhanced IL-18 production in gastric cancer cells, and the VEGF-enhanced IL-18 production significantly increased the migration of SNU-601 cells. This suggests that rhVEGF-165 affects the metastasis of gastric cancer cells by not only regulating angiogenesis but also enhancing the ability of these cells to migrate as a result of VEGF-enhanced IL-18 production. This study found that IL-18 induced the migration of SNU-601 cells through f-actin polymerization and tensin downregulation (Figure 4 ). F-actin polymerization by IL-18 was mainly distributed in the cortical region around the nuclei. IL-18 induced a change in cell morphology to a round form, suggesting weaker adherence. In addition, tensin expression, which inhibits actin polymerization, was increased markedly in IL-18 siRNA-transfected cells, and was reduced by rhIL-18. This means that IL-18 downregulates tensin expression for promoting f-actin polymerization. It was reported that tensin retards the initial f-actin polymerization, and considerably decreases f-actin elongation (Lo et al., 1994) . Taken together, rhIL-18 can induce f-actin polymerization directly, and reduce the expression of tensin for f-actin polymerization. Besides migration, IL-18 affects the invasion of SNU-601 cells (Figure 3e ). It was reported that IL-18 increased myeloid leukemia and human NK cell invasion through the upregulation of matrix metalloproteinases (MMP) expression (Ishida et al., 2004; Zhang et al., 2004) . Because MMP are important proteins involved in the processes of tumor Effect of IL-18 on VEGF-enhanced migration K-E Kim et al invasion and metastasis, it is believed that IL-18 can regulate MMP expression, resulting in enhanced invasion. In this study, rhVEGF-165 was found to enhance IL-18 production, suggesting that rhVEGF-165 stimulates the intracellular pathway of IL-18 production. Previously, it was reported that ultraviolet (UV) radiation increases IL-18 production in the human keratinocyte cell line, HaCaT. UV-enhanced IL-18 production requires the generation of ROI (Cho et al., 2002) . It was hypothesized that VEGF might enhance IL-18 production in gastric cancer cells via ROI generation. VEGF-enhanced IL-18 production was reduced significantly by NAC, and ROI level was increased by rhVEGF-165 (Figure 5 ), indicating that ROI are common factors for the intracellular mechanism of IL-18 production. ERK1/2 occurs downstream of VEGF-induced VEGFR-2 phosphorylation (Pedram et al., 1998) . Therefore, this study examined whether or not ERK1/2 pathway is involved in the intracellular pathway of VEGF-enhanced IL-18 production mechanism. Figure 6 shows that PD98059 decreased the level of VEGF-enhanced IL-18 production, and that rhVEGF-165 can activate ERK1/2 directly. This suggests that ERK1/2 is involved in the intracellular pathway of VEGF-enhanced IL-18 production. Although NAC decreased the spontaneous production of IL-18 from SNU-601 cells, PD98059 had no affect in the absence of rhVEGF-165 (data not shown). This indicates that ERK1/2 is specifically associated with the VEGFenhanced IL-18 production. In conclusion, rhVEGF-165 increases IL-18 production in the gastric cancer cell line, SNU-601, through the generation of ROI and the Figure 6 rhVEGF-165 enhances IL-18 production through the generation of ROI and the activation of ERK1/2 pathway. (a) SNU-601 cells were pretreated with or without 5 mM of NAC, and incubated with 50 ng/ml of rhVEGF-165. The cultured supernatants were collected, and the IL-18 concentration was determined by ELISA. (b) SNU-601 cells (9 Â 10 4 cells/well) were incubated with (VEGF) or without (control) 50 ng/ml of rhVEGF-165 in wells of 96-well plate, and 50 mM of DCFH-DA was then added to indicate the level of ROI. After incubation for 10 min, the level of ROI was measured using a fluorometer. (c) Before incubation with rhVEGF-165, SNU-601 cells were pretreated with or without a specific inhibitor of ERK1/2 or JNK for 1 h. (d) SNU-601 cells were pretreated with or without 12.5 or 25 mM PD98059. The cultured supernatants were collected, and the IL-18 concentration was determined by ELISA. A representative experiment of three experiments performed independently is shown; bars, mean7s.e. *Po0.05 versus control. (e) The cells were treated with 50 ng/ml of rhVEGF-165 for 2.5, 5, 10 and 15 min. After cell lysis, the level of ERK1/2 phosphorylation was determined by Western blot analysis. The total ERK1/2 was used to confirm the equal volume of the cell lysates. activation of ERK1/2 pathway. As a result of VEGFenhanced IL-18 production, the migration of SNU-601 cells was increased through f-actin polymerization and tensin downregulation. This suggests that rhVEGF-165 regulates the migratory process by enhancing IL-18 production. Taken together, it is proposed that VEGFenhanced IL-18 production plays an important role in the pathogenesis of gastric cancer.
Materials and methods
Cell line
The human gastric cancer cell lines, SNU-601, SNU-719 and MKN-28, were obtained from the Korean Cell Line Bank of the Cancer Research Center, Seoul National University College of Medicine. These cell lines were cultured in Roswell Park Memorial Institute 1640 medium (Invitrogen Corporation, San Diego, CA, USA) containing 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% heatinactivated fetal bovine serum (FBS), and were maintained in a 5% CO 2 incubator at 371C.
Flow cytometry
Indirect fluorescence-activated cell sorter (FACS) analysis was performed to detect VEGFR-2 and IL-18R-a expression. Briefly, the cells were washed twice with phosphate-buffered saline (PBS), and stained with either mouse anti-human VEGFR-2 antibody (Sigma, St Louis, MO, USA) or mouse antihuman IL-18R antibody (R&D systems Inc., Minneapolis, MN, USA) for 30 min on ice. The cells were further stained with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G (IgG) antibody (DiNonA) for 30 min on ice, followed by two washes with PBS. An FACS Calibur (Becton Dickinson, Mountain View, CA, USA) flow cytometer was used for analysis.
Migration and invasion assay
Migration assay was performed using a Transwell chamber (Corning) with 8 mm pore polycarbonate filters. Briefly, the cells were suspended in serum-free media. One hundred microliters of the cell suspension (5 Â 10 5 cells/ml) was placed into the upper chamber, and a medium containing serum was placed into the lower chamber. After incubation for 24 h, the cells that penetrated through the pores in the membrane were stained with a staining solution (0.1% crystal violet in ethanol). The stained cells were resolved in 10% acetic acid.
The OD values at 570 nm were measured using an ELISA reader (Molecular Devices, Sunnyvale, CA, USA). Invasion assay was determined using an extracellular matrix (ECM)-based assay. The upper chamber was coated with an ECM gel (Sigma), which forms a reconstituted basement membrane at 371C. After washing three times, migration assay was performed.
RT-PCR
Total RNA was isolated, and the cDNA was then made. After reverse transcription, the cDNA was incubated with either human IL-18 primers (sense, 5 0 -AGGAATAAAGATGG CTGCTGAAC-3 0 ; antisense, 5 0 -GCTCACCACAACCTCTA CCTCC-3 0 ; target size, 837 bp) or human b-actin primers (sense, 5 0 -TAGCGGGGTTCACCCACACTGTGCCCCATC TA-3 0 ; antisense, 5 0 -CTAGAAGCATTTGCGGTGGACCG ATGGAGGG-3 0 ; target size, 661 bp) for PCR amplification. The cycling conditions for IL-18 were 1 min at 951C, 1 min at 58.51C, 45 s at 721C for 35 cycles, and for b-actin were 30 s at 941C, 30 s at 561C, 1 min at 721C for 30 cycles.
ELISA
In anti-human IL-18 antibody-coated wells, the cultured supernatants were added along with biotinylated detection antibody. After incubating the cultured supernatant for 3 h, the wells were washed three times with a washing solution. Streptavidin-horseradish peroxidase (HRP) was then added for 30 min, and substrate 3,3 0 ,5,5 0 -tetramethyl benzidine solution was added for 40 min at 371C in the dark. Color development was stopped using H 2 SO 4 stop solution, and the OD values at 450 nm were measured by using an ELISA reader (Molecular Devices).
Measurement of intracellular ROI level Cells (9 Â 10 4 cells/well) were incubated in 96-well plate for 30 min, and 50 mM 2 0 ,7 0 -dichlorofluorescein diacetate (DCFH-DA; Sigma) was then added. After incubation, the intracellular ROI levels were measured using a fluorometer (Molecular Devices) at an excitation and emission wavelength of 485 and 538 nm, respectively.
Immunofluorescence staining Cells were fixed with 4% paraformaldehyde in PBS for 20 min, and then permeabilized for 30 min with 0.5% Triton X-100 in PBS. After blocking with 3% FBS in PBS, the level of f-actin polymerization was detected by incubating the cells with FITC-conjugated phalloidin (Molecular Probes Inc., Eugene, OR, USA) for 1 h. F-actin was detected using a confocal microscope system (Olympus FV-300, 400 Â objective, FLUOVIEW imaging program).
Immunoprecipitation and Western blot
Cells were washed with ice-cold PBS and extracted with an icecold lysis buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% deoxycholic acid sodium salt, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid and protein inhibitor cocktail). For the detection of tensin expression, 1 mg of the protein was exposed to 2 mg of mouse anti-human tensin antibody and protein-G agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The protein was separated by 8% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose transfer membrane (Schleicher & Schuell Inc., Keene, NH, USA). The membrane was blocked with 5% non-fat dried milk for 1 h, and incubated overnight with anti-human tensin antibody. After washing, the membrane was incubated with rabbit anti-mouse IgG antibody conjugated with biotin for 1 h. After incubation with HRP for 30 min, each of the proteins was detected using an enhanced chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK). For the detection of ERK1/2, the protein was separated by 12% SDS-PAGE, and examined using mouse anti-human phospho-ERK1/2 antibody or rabbit anti-human total ERK1/2 antibody (Cell Signaling Technology, Danvers, MA, USA).
